# Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia

> **NCT04103450** · PHASE3 · COMPLETED · sponsor: **Urovant Sciences GmbH** · enrollment: 276 (actual)

## Conditions studied

- Overactive Bladder

## Interventions

- **DRUG:** Vibegron

## Key facts

- **NCT ID:** NCT04103450
- **Lead sponsor:** Urovant Sciences GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-19
- **Primary completion:** 2022-07-29
- **Final completion:** 2022-07-29
- **Target enrollment:** 276 (ACTUAL)
- **Last updated:** 2024-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04103450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04103450, "Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04103450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*